In 2012, an article titled “Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.” was published by IN Colmers et al. in Canadian Medical Association Journal investigating the relationship between Actos and bladder cancer.  Thiazolidinediones are a class of diabetes drugs including pioglitazone, the chemical name for the drug Actos.

This article states “Patients with type 2 diabetes have a 40% increased risk of bladder cancer. Thiazolidinediones, especially pioglitazone, may increase the risk,” and as such, the authors “conducted a systematic review and meta-analysis to evaluate the risk of bladder cancer among adults with type 2 diabetes taking thiazolidinediones.”

To perform this study, the team reviewed a number of previously-conducted studies, both randomized controlled studies, and “case-control studies that reported incident bladder cancer among people with type 2 diabetes who ever (v. never) were exposed to pioglitazone (main outcome), rosiglitazone or any thiazolidinedione.”

Using statistical analysis, the team found that thiazolidinedione use was associated with a 15% increased risk of bladder cancer, and that Actos use was associated with a 22% increased risk of bladder cancer.

Due to the fact that the manufacturers of Actos have failed time and again to make clear the risk for bladder cancer, a number of Actos bladder cancer lawsuits have been filed.  If you or a loved one used Actos and suffered bladder cancer, you may be entitled to significant financial compensation for your injuries.  For a free, no-obligation case consultation, contact our team of Actos bladder cancer lawyers at the information provided below.  We have the compassion, experience, and resources required to win the justice you deserve.

(855) 452 – 5529